Insights into antiamyloidogenic properties of the green tea extract (-)-epigallocatechin-3-gallate toward metal-associated amyloid-β species

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 10, 2013, Pages 3743-3748

  Hyung, Suk Joon ^a   Detoma, Alaina S ^a   Brender, Jeffrey R ^a   Lee, Sanghyun ^a   Vivekanandan, Subramanian ^a   Kochi, Akiko ^a   Choi, Jung Suk ^a   Ramamoorthy, Ayyalusamy ^a   Ruotolo, Brandon T ^a   Lim, Mi Hee ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Amyloid peptide; Amyloidogenesis; Metal ions; Natural products

Indexed keywords

(2,3) 5,7 DIHYDROXY 2 (3,4,5 TRIHYDROXYPHENYL) 3,4 DIHYDRO 2H 1 BENZOPYRAN 3 YL 3,4,5 TRIHYDROXYBENZOATE; AMYLOID BETA PROTEIN; COPPER ION; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; METAL; MONOMER; NOOTROPIC AGENT; UNCLASSIFIED DRUG; ZINC;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; IN VITRO STUDY; ION MOBILITY SPECTROMETRY; MODULATION; MOLECULAR MODEL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN STRUCTURE; TEA;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CAMELLIA SINENSIS; CATECHIN; COPPER; HUMANS; METALS; MODELS, MOLECULAR; NEUROPROTECTIVE AGENTS; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDE FRAGMENTS; PLANT EXTRACTS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; TANDEM MASS SPECTROMETRY; ZINC;

EID: 84874609836     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1220326110     Document Type: Article

References (51)

1. DeToma AS, Salamekh S, Ramamoorthy A, Lim MH (2012) Misfolded proteins in Alzheimer's disease and type II diabetes. Chem Soc Rev 41(2):608-621.
2. Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10(Suppl):S10-S17.
3. Kepp KP (2012) Bioinorganic chemistry of Alzheimer's disease. Chem Rev 112(10): 5193-5239.
4. Jakob-Roetne R, Jacobsen H (2009) Alzheimer's disease: From pathology to therapeutic approaches. Angew Chem Int Ed Engl 48(17):3030-3059.
5. Crouch PJ, Barnham KJ (2012) Therapeutic redistribution of metal ions to treat Alzheimer's disease. Acc Chem Res 45(9):1604-1611.
6. Que EL, Domaille DW, Chang CJ (2008) Metals in neurobiology: Probing their chemistry and biology with molecular imaging. Chem Rev 108(5):1517-1549.
7. Eskici G, Axelsen PH (2012) Copper and oxidative stress in the pathogenesis of Alzheimer's disease. Biochemistry 51(32):6289-6311.
8. Pithadia AS, Lim MH (2012) Metal-associated amyloid-β species in Alzheimer's disease. Curr Opin Chem Biol 16(1-2):67-73.
9. Rodríguez-Rodríguez C, Telpoukhovskaia M, Orvig C (2012) The art of building multifunctional metal-binding agents from basic molecular scaffolds for the potential application in neurodegenerative diseases. Coord Chem Rev 256(19-20):2308-2332.
10. Braymer JJ, DeToma AS, Choi J-S, Ko KS, Lim MH (2011) Recent development of bifunctional small molecules to study metal-amyloid-β species in Alzheimer's disease. Int J Alzheimers Dis 2011:623051.
11. Perez LR, Franz KJ (2010) Minding metals: Tailoring multifunctional chelating agents for neurodegenerative disease. Dalton Trans 39(9):2177-2187.
12. Pithadia AS, et al. (2012) Reactivity of diphenylpropynone derivatives toward metalassociated amyloid-β species. Inorg Chem 51(23):12959-12967.
13. 42 peptide. J Am Chem Soc 134(15):6625-6636.
14. Choi J-S, Braymer JJ, Nanga RPR, Ramamoorthy A, Lim MH (2010) Design of small molecules that target metal-Aβ species and regulate metal-induced Aβ aggregation and neurotoxicity. Proc Natl Acad Sci USA 107(51):21990-21995.
15. Braymer JJ, et al. (2011) Development of bifunctional stilbene derivatives for targeting and modulating metal-amyloid-β species. Inorg Chem 50(21):10724-10734.
16. Rodríguez-Rodríguez C, et al. (2009) Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. J Am Chem Soc 131(4):1436-1451.
17. Hindo SS, et al. (2009) Small molecule modulators of copper-induced Aβ aggregation. J Am Chem Soc 131(46):16663-16665.
18. Wu W-h, et al. (2008) Sequestration of copper from β-amyloid promotes selective lysis by cyclen-hybrid cleavage agents. J Biol Chem 283(46):31657-31664.
19. Porat Y, Abramowitz A, Gazit E (2006) Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 67(1):27-37.
20. Ehrnhoefer DE, et al. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15(6):558-566.
21. Bieschke J, et al. (2010) EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity. Proc Natl Acad Sci USA 107(17):7710-7715.
22. Ladiwala ARA, Dordick JS, Tessier PM (2011) Aromatic small molecules remodel toxic soluble oligomers of amyloid β through three independent pathways. J Biol Chem 286(5):3209-3218.
23. Lemkul JA, Bevan DR (2012) Morin inhibits the early stages of amyloid β-peptide aggregation by altering tertiary and quaternary interactions to produce "off-pathway" structures. Biochemistry 51(30):5990-6009.
24. Sinha S, et al. (2012) Comparison of three amyloid assembly inhibitors: The sugar scyllo-inositol, the polyphenol epigallocatechin gallate, and the molecular tweezer CLR01. ACS Chem Neurosci 3(6):451-458.
25. Lopez del Amo JM, et al. (2012) Structural properties of EGCG-induced, nontoxic Alzheimer's disease Aβ oligomers. J Mol Biol 421(4-5):517-524.
26. DeToma AS, Choi J-S, Braymer JJ, Lim MH (2011) Myricetin: A naturally occurring regulator of metal-induced amyloid-β aggregation and neurotoxicity. ChemBioChem 12(8):1198-1201.
27. Kim J, Lee HJ, Lee KW (2010) Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J Neurochem 112(6):1415-1430.
28. Meng F, Abedini A, Plesner A, Verchere CB, Raleigh DP (2010) The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry 49(37):8127-8133.
29. Chandrashekaran IR, Adda CG, MacRaild CA, Anders RF, Norton RS (2010) Inhibition by flavonoids of amyloid-like fibril formation by Plasmodium falciparum merozoite surface protein 2. Biochemistry 49(28):5899-5908.
30. Chandrashekaran IR, Adda CG, MacRaild CA, Anders RF, Norton RS (2011) EGCG disaggregates amyloid-like fibrils formed by Plasmodium falciparum merozoite surface protein 2. Arch Biochem Biophys 513(2):153-157.
31. Popovych N, et al. (2012) Site specific interaction of the polyphenol EGCG with the SEVI amyloid precursor peptide PAP(248-286). J Phys Chem B 116(11):3650-3658.
32. Pirker KF, Baratto MC, Basosi R, Goodman BA (2012) Influence of pH on the speciation of copper(II) in reactions with the green tea polyphenols, epigallocatechin gallate and gallic acid. J Inorg Biochem 112:10-16.
33. 2+ enhances inhibitory effects of EGCG on the growth of PC-3 cells. Mol Nutr Food Res 52(4):465-471.
34. Cheng XR, et al. (2013) Surface plasmon resonance imaging of amyloid-β aggregation kinetics in the presence of epigallocatechin gallate and metals. Anal Chem, 10.1021/ac303181q.
35. Ruotolo BT, Benesch JLP, Sandercock AM, Hyung S-J, Robinson CV (2008) Ion mobilitymass spectrometry analysis of large protein complexes. Nat Protoc 3(7):1139-1152.
36. Bernstein SL, et al. (2009) Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem 1(4): 326-331.
37. Mancino AM, Hindo SS, Kochi A, Lim MH (2009) Effects of clioquinol on metaltriggered amyloid-β aggregation revisited. Inorg Chem 48(20):9596-9598.
38. Suzuki Y, Brender JR, Hartman K, Ramamoorthy A, Marsh ENG (2012) Alternative pathways of human islet amyloid polypeptide aggregation distinguished by 19F nuclear magnetic resonance-detected kinetics of monomer consumption. Biochemistry 51(41):8154-8162.
39. Ashcroft AE (2010) Mass spectrometry and the amyloid problem-how far can we go in the gas phase? J Am Soc Mass Spectrom 21(7):1087-1096.
40. Reinke AA, Gestwicki JE (2011) Insight into amyloid structure using chemical probes. Chem Biol Drug Des 77(6):399-411.
41. Larson JL, Ko E, Miranker AD (2000) Direct measurement of islet amyloid polypeptide fibrillogenesis by mass spectrometry. Protein Sci 9(2):427-431.
42. Hortschansky P, Schroeckh V, Christopeit T, Zandomeneghi G, Fändrich M (2005) The aggregation kinetics of Alzheimer's β-amyloid peptide is controlled by stochastic nucleation. Protein Sci 14(7):1753-1759.
43. Baumketner A, et al. (2006) Amyloid β-protein monomer structure: A computational and experimental study. Protein Sci 15(3):420-428.
44. El-Hawiet A, Kitova EN, Liu L, Klassen JS (2010) Quantifying labile protein-ligand interactions using electrospray ionization mass spectrometry. J Am Soc Mass Spectrom 21(11):1893-1899.
45. Wang S-H, Liu F-F, Dong X-Y, Sun Y (2010) Thermodynamic analysis of the molecular interactions between amyloid β-peptide 42 and (-)-epigallocatechin-3-gallate. J Phys Chem B 114(35):11576-11583.
46. Vivekanandan S, Brender JR, Lee SY, Ramamoorthy A (2011) A partially folded structure of amyloid-beta(1-40) in an aqueous environment. Biochem Biophys Res Commun 411(2):312-316.
47. Rauk A (2009) The chemistry of Alzheimer's disease. Chem Soc Rev 38(9):2698-2715.
48. Rezaei-Ghaleh N, Giller K, Becker S, Zweckstetter M (2011) Effect of zinc binding on β-amyloid structure and dynamics: Implications for Aβ aggregation. Biophys J 101(5): 1202-1211.
49. Faller P (2009) Copper and zinc binding to amyloid-β: Coordination, dynamics, aggregation, reactivity and metal-ion transfer. ChemBioChem 10(18):2837-2845.
50. Mesleh MF, Hunter JM, Shvartsburg AA, Schatz GC, Jarrold MF (1996) Structural information from ion mobility measurements: Effects of the long-range potential. J Phys Chem 100(40):16082-16086.
51. Shvartsburg AA, Jarrold MF (1996) An exact hard-spheres scattering model for the mobilities of polyatomic ions. Chem Phys Lett 261(1-2):86-91.